Amygdalin Enhances the Antitumor Effect of Sorafenib
Elmetwalli, A., Abdel Khalek, A., El-Naggar, S., El-Magd, M., Salama, A. (2021). Amygdalin Enhances the Antitumor Effect of Sorafenib. EKB Journal Management System, 13(2), 61-68. doi: 10.21608/eajbsd.2021.196336
Alaa Elmetwalli; Aya M. Abdel Khalek; Sabry A. El-Naggar; Mohammed A. El-Magd; Afrah F. Salama. "Amygdalin Enhances the Antitumor Effect of Sorafenib". EKB Journal Management System, 13, 2, 2021, 61-68. doi: 10.21608/eajbsd.2021.196336
Elmetwalli, A., Abdel Khalek, A., El-Naggar, S., El-Magd, M., Salama, A. (2021). 'Amygdalin Enhances the Antitumor Effect of Sorafenib', EKB Journal Management System, 13(2), pp. 61-68. doi: 10.21608/eajbsd.2021.196336
Elmetwalli, A., Abdel Khalek, A., El-Naggar, S., El-Magd, M., Salama, A. Amygdalin Enhances the Antitumor Effect of Sorafenib. EKB Journal Management System, 2021; 13(2): 61-68. doi: 10.21608/eajbsd.2021.196336

Amygdalin Enhances the Antitumor Effect of Sorafenib

Egyptian Academic Journal of Biological Sciences, D. Histology & Histochemistry
Article 5, Volume 13, Issue 2, December 2021, Page 61-68  XML PDF (726.58 K)
Document Type: Original Article
DOI: 10.21608/eajbsd.2021.196336
View on SCiNiTO View on SCiNiTO
Authors
Alaa Elmetwalli1; Aya M. Abdel Khalek2; Sabry A. El-Naggar3; Mohammed A. El-Magd4; Afrah F. Salama2
1Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt
2Biochemistry Section, Chemistry Department, Faculty of Science, Tanta University, Egypt
3Zoology Department, Faculty of Science, Tanta University, Egypt
4Anatomy and Embryology Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Egypt
Abstract
Sorafenib (SOR) is a potent chemotherapeutic agent used for cancer treatment, however, it has several side effects upon administration on some vital organs. Amygdalin (AMY) is a vitamin B-17 that showed several biological activities as an antioxidant, anti-inflammatory, and anticancer agent. This study was conducted to evaluate the effect of the treatment with a combination of SOR/AMY in Ehrlich ascites carcinoma (EAC)-bearing mice. Twenty-four female CD-1 mice were divided into four groups (n=6) as follows: Group 1 (Gp1) was inoculated with 2 × 106 EAC-cells/mouse and served as a positive control. Gp2, 3, and 4 were inoculated with the same number of EAC-cells as in Gp1, and then injected with AMY (50 mg/Kg/14 days), SOR (10 mg/Kg/14 days), and AMY/SOR intraperitoneal (i.p.), respectively. Bodyweight changes, hematological changes, and antitumor indices were evaluated post-treatments. The results showed that AMY had a slight antitumor effect against EAC-bearing mice. Compared to EAC-bearing mice treated with SOR alone, EAC-bearing mice treated with AMY/SOR showed a decrease in the final body weight, tumor volumes, tumor cells count, totally live and dead tumor cells. Furthermore, treatment with AMY/SOR ameliorated the hematological changes. In summary, co-treatment with AMY enhanced SOR antitumor efficacy in EAC-bearing mice. 
Keywords
Antitumor; Amygdalin; Sorafenib; EAC-bearing mice
Statistics
Article View: 360
PDF Download: 536